478 related articles for article (PubMed ID: 35626167)
1. MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.
Kast RE; Alfieri A; Assi HI; Burns TC; Elyamany AM; Gonzalez-Cao M; Karpel-Massler G; Marosi C; Salacz ME; Sardi I; Van Vlierberghe P; Zaghloul MS; Halatsch ME
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626167
[TBL] [Abstract][Full Text] [Related]
2. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3.
Halatsch ME; Kast RE; Karpel-Massler G; Mayer B; Zolk O; Schmitz B; Scheuerle A; Maier L; Bullinger L; Mayer-Steinacker R; Schmidt C; Zeiler K; Elshaer Z; Panther P; Schmelzle B; Hallmen A; Dwucet A; Siegelin MD; Westhoff MA; Beckers K; Bouche G; Heiland T
Neurooncol Adv; 2021; 3(1):vdab075. PubMed ID: 34377985
[TBL] [Abstract][Full Text] [Related]
3. IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone.
Kast RE
Oncoscience; 2024; 11():15-31. PubMed ID: 38524376
[TBL] [Abstract][Full Text] [Related]
4. In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma.
Halatsch ME; Dwucet A; Schmidt CJ; Mühlnickel J; Heiland T; Zeiler K; Siegelin MD; Kast RE; Karpel-Massler G
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959641
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.
Kast RE; Halatsch ME; Rosell R
Cells; 2021 May; 10(5):. PubMed ID: 34068720
[TBL] [Abstract][Full Text] [Related]
7. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Kast RE; Karpel-Massler G; Halatsch ME
Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
[TBL] [Abstract][Full Text] [Related]
8. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Kast RE; Boockvar JA; Brüning A; Cappello F; Chang WW; Cvek B; Dou QP; Duenas-Gonzalez A; Efferth T; Focosi D; Ghaffari SH; Karpel-Massler G; Ketola K; Khoshnevisan A; Keizman D; Magné N; Marosi C; McDonald K; Muñoz M; Paranjpe A; Pourgholami MH; Sardi I; Sella A; Srivenugopal KS; Tuccori M; Wang W; Wirtz CR; Halatsch ME
Oncotarget; 2013 Apr; 4(4):502-30. PubMed ID: 23594434
[TBL] [Abstract][Full Text] [Related]
9. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
10. Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.
Kast RE; Skuli N; Karpel-Massler G; Frosina G; Ryken T; Halatsch ME
Oncotarget; 2017 Sep; 8(37):60727-60749. PubMed ID: 28977822
[TBL] [Abstract][Full Text] [Related]
11. Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells.
Duarte D; Guerreiro I; Vale N
Curr Issues Mol Biol; 2022 Oct; 44(10):4930-4949. PubMed ID: 36286050
[TBL] [Abstract][Full Text] [Related]
12. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
13. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
14. Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action.
Duarte D; Nunes M; Ricardo S; Vale N
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291699
[TBL] [Abstract][Full Text] [Related]
15. A Potential New Treatment for High-Grade Glioma: A Study Assessing Repurposed Drug Combinations against Patient-Derived High-Grade Glioma Cells.
Lastakchi S; Olaloko MK; McConville C
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681582
[TBL] [Abstract][Full Text] [Related]
16. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
17. Repurposing Drugs in Small Animal Oncology.
Giuliano A; Horta RS; Vieira RAM; Hume KR; Dobson J
Animals (Basel); 2022 Dec; 13(1):. PubMed ID: 36611747
[TBL] [Abstract][Full Text] [Related]
18. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
19. The potential to treat lung cancer via inhalation of repurposed drugs.
Lee WH; Loo CY; Ghadiri M; Leong CR; Young PM; Traini D
Adv Drug Deliv Rev; 2018 Aug; 133():107-130. PubMed ID: 30189271
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
